Efficacy and Safety of Longidaza ® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19

Conditions: Post-Acute COVID-19 Syndrome; Lung Disease With Polymyositis; Fibrosis; Lung Diseases, Interstitial; Lung; Disease, Interstitial, With Fibrosis Interventions: Drug: Longidaza ®; Drug: Placebo Sponsors: NPO Petrovax Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials